Cross-Therapy Area Leader, Global Epidemiology
Johnson & Johnson, Switzerland
Daniel Rosenberg has worked as a pharmacoepidemiologist in the pharmaceutical industry in both large and small companies for over 20 years. He started his career with a Post Doctoral fellowship under the direction of Prof. Dr. Harry Guess in Pharmacoepidemiology at University of North Carolina, followed by nearly a decade at GlaxoSmithKline in the UK and Singapore. He founded the Epidemiology group at Actelion pharmaceuticals and led this group until Johnson and Johnson’s acquisition of Actelion in 2017. In his present position at J&J within the Global Epidemiology department, He leads a Cross Therapy Area Group of different Disease Area Epidemiology Teams and the Rare Disease Epicenter team. In addition to his interest in rare diseases, Daniel continues his work to shape and develop the use of RWE in the regulatory setting, and currently serves as the EFPIA lead representative to the ICH M14 Expert Working Group who are developing a harmonized guidance on the use of real-world data in pharmacoepidemiology studies for safety assessment. Currently, He chairs the ISPE Rare Disease Special interest group (SIG).